Sheller Gives Presentations on Risperdal and Opioid Litigation

0
Shares

Stephen A. Sheller, founder of Sheller PC, is often sought for his expertise in litigation against pharmaceutical manufacturers whose products cause harm to consumers. He recently has one of few private law firms chosen to work with the City of Philadelphia in opioid litigation.

In October 2019 Sheller was an invited speaker at two conferences.

October 12, 2019 “Big Pharma, Big Greed”

Named after his book “Big Pharma, Big Greed” released earlier this year, Stephen Sheller gave a presentation with Q&A to the International Society for Ethical Psychology & Psychiatry. Sheller’s remarks included developments in the Philadelphia’s opioid case and his firm’s litigation against pharmaceutical giant Johnson & Johnson for the antipsychotic drug Risperdal. 

“Mental illness is being used as an excuse to sell antipsychotics, particularly Risperdal, for kids. In my view it’s nuttier than any of the so called illnesses they are prescribing it for long term. The new game in town is autism for which Risperdal is used all too often.”

Screen Shot 2019-11-29 at 11.17.47 AM

October 23, 2019 “The Unique Impact of the Opioid Crisis in the United States – What You Need to Know”

Stephen Sheller was one of five experts at the Widener University Delaware School Law School’s 2019 Food and Drug Law Symposium discussing the opioid crisis. Sheller’s covered the topic of ‘Multidisctrict Litigation Focusing on the Ethical Bias Motion; Case Review & Status.’

Previous post

Will Fines Change Corporate Culture That Caused Opioid Crisis?

Next post

Thousands of Risperdal Cases Previously Time-Barred, Reopened